Biology Reference
In-Depth Information
16. Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn 2nd GW, Koch WJ. Reduction
of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart fail-
ure progression and improves cardiac function after myocardial infarction. J Biol Chem .
2010;285:16378 - 16386.
17. Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. Modulation of adrenal
catecholamine secretion by in vivo gene transfer and manipulation of G protein-
coupled receptor kinase-2 activity. Mol Ther . 2008;16:302- 307.
18. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-
tuning cardiac stimulation. Trends Mol Med . 2007;13:503 - 511.
19. Wang Q, Zhao J, Brady AE, et al. Spinophilin blocks arrestin actions in vitro and
in vivo at G protein-coupled receptors. Science . 2004;304:1940- 1944.
20. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin
regulation. Pharmacol Ther . 2009;121:285- 293.
21. Rengo G, Lymperopoulos A, Koch WJ. Future G protein-coupled receptor targets for
treatment of heart failure. Curr Treat Options Cardiovasc Med . 2009;11:328- 338.
22. Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adeno-associated virus
serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neu-
rohormonal axis in chronic heart failure. Circulation . 2009;119:89 - 98.
23. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy tar-
get in heart failure. J Mol Cell Cardiol . 2011;50:785- 792.
24. Lymperopoulos A, Rengo G, Koch WJ. GRK2 inhibition in heart failure: something
old, something new. Curr Pharm Des . 2012;18:186 - 191.
25. Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic
receptor
transactivation of
the EGFR confers cardioprotection.
J Clin Invest .
2007;117:2445- 2458.
26. Tilley DG. G protein-dependent and G protein-independent signaling pathways and
their impact on cardiac function. Circ Res . 2011;109:217- 230.
27. Noor N, Patel CB, Rockman HA. b -arrestin: a signaling molecule and potential ther-
apeutic target for heart failure. J Mol Cell Cardiol . 2011;51:534- 541.
28. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular
signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA .
2001;98:2449- 2454.
29. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. Beta-arrestin inhibits
NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor
IkappaBalpha. Proc Natl Acad Sci USA . 2004;101:8603- 8607.
30. Gao H, Sun Y, Wu Y, et al. Identification of beta-arrestin2 as a G protein-coupled
receptor-stimulated regulator of NF-kappaB pathways. Mol Cell . 2004;14:303- 317.
31. Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overexpression of AT1 recep-
tor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in
transgenic mice. J Clin Invest . 2005;115:3045 - 3056.
32. Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated
kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct pheno-
types of cardiac myocytes. Basic Clin Pharmacol Toxicol . 2007;100:296- 301.
33. Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of
the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA .
2006;103:16284 - 16289.
34. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. Beta-arrestin-biased
agonism of the angiotensin receptor induced by mechanical stress. Sci Signal . 2010;3:
ra46.
35. Kim J, Zhang L, Peppel K, et al. Beta-arrestins regulate atherosclerosis and neointimal
hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res .
2008;103:70- 79.
 
Search WWH ::




Custom Search